Cellosaurus cell line SK-MEL-93 DX-3 (CVCL_5650)

• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=9598804).
  
• Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
  

PubMed=6976407; DOI=10.1084/jem.154.6.1764
Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient Implications for the study of tumor antigens.
J. Exp. Med. 154:1764-1778(1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=6744277
Kozlowski J.M., Fidler I.J., Campbell D., Xu Z.-L., Kaighn M.E., Hart I.R.
Metastatic behavior of human tumor cell lines grown in the nude mouse.
Cancer Res. 44:3522-3529(1984)

PubMed=2983346; DOI=10.1073/pnas.82.5.1470
Dracopoli N.C., Houghton A.N., Old L.J.
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985)

PubMed=2886213
Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma.
Cancer Res. 47:3995-4000(1987)

PubMed=2297053
Schackert G., Price J.E., Zhang R.-D., Bucana C.D., Itoh K., Fidler I.J.
Regional growth of different human melanomas as metastases in the brain of nude mice.
Am. J. Pathol. 136:95-102(1990)

PubMed=1716514
Albino A.P., Davis B.M., Nanus D.M.
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.
Cancer Res. 51:4815-4820(1991)

PubMed=2060182; DOI=10.1007/BF01753726
Easty D.J., Hart I.R., Patel K., Seymour C., Yacoub M.H., Domscheit A., Gunther S., Postel W., Gorg A., Dunn M.J.
Changes in protein expression during melanoma differentiation determined by computer analysis of 2-D gels.
Clin. Exp. Metastasis 9:221-230(1991)

PubMed=7780963
Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A., Toso R.J., Herlyn M., Bennett D.C.
Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression.
Cancer Res. 55:2528-2532(1995)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)